As research progresses in the understanding of the molecular and cellular mechanisms underlying neurodegenerative diseases like Huntington's disease (HD) and expands towards preclinical work for the development of new therapies, highly relevant animal models are increasingly needed to test new hypotheses and to validate new therapeutic approaches. In this light, we characterized an excitotoxic lesion model of striatal dysfunction in non-human primates (NHPs) using cognitive and motor behaviour assessment as well as functional imaging and post-mortem anatomical analyses. NHPs received intra-striatal stereotaxic injections of quinolinic acid bilaterally in the caudate nucleus and unilaterally in the left sensorimotor putamen. Post-operative MRI scans showed atrophy of the caudate nucleus and a large ventricular enlargement in all 6 NHPs that correlated with post-mortem measurements. Behavioral analysis showed deficits in 2 analogues of the Wisconsin card sorting test (perseverative behavior) and in an executive task, while no deficits were observed in a visual recognition or an episodic memory task at 6 months following surgery. Spontaneous locomotor activity was decreased after lesion and the incidence of apomorphine-induced dyskinesias was significantly increased at 3 and 6 months following lesion. Positron emission tomography scans obtained at end-point showed a major deficit in glucose metabolism and D2 receptor density limited to the lesioned striatum of all NHPs compared to controls. Post-mortem analyses revealed a significant loss of medium-sized spiny neurons in the striatum, a loss of neurons and fibers in the globus pallidus, a unilateral decrease in dopaminergic neurons of the substantia nigra and a loss of neurons in the motor and dorsolateral prefrontal cortex. Overall, we show that this robust NHP model presents specific behavioral (learning, execution and retention of cognitive tests) and metabolic functional deficits that, to the best of our knowledge, are currently not mimicked in any available large animal model of striatal dysfunction. Moreover, we used non-invasive, translational techniques like behavior and imaging to quantify such deficits and found that they correlate to a significant cell loss in the striatum and its main input and output structures. This model can thus significantly contribute to the pre-clinical longitudinal evaluation of the ability of new therapeutic cell, gene or pharmacotherapy approaches in restoring the functionality of the striatal circuitry.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.nbd.2019.104484 | DOI Listing |
Alzheimers Dement
December 2024
Yonsei University College of Medicine, Seoul, Korea, Republic of (South).
Background: To investigate the relationship between basal forebrain (BF) cholinergic activity, dopaminergic degeneration, white matter hyperintensities (WMHs), and their effects on clinical manifestations of Alzheimer's disease (AD) and Lewy body disease (LBD).
Method: A total of 407 subjects who underwent 3-T MRI, dopamine transporter (DAT) positron emission tomography, neuropsychological tests, and assessments for parkinsonism, cognitive fluctuation (CF), visual hallucination (VH), and rapid eye movement sleep behavior disorder (RBD) were evaluated for probable AD, LBD, or both (AD+LBD). General linear models were used to investigate the relationships between BF volume (BFV), striatal DAT uptake, WMHs, and clinical manifestations after controlling for age, sex, education, vascular factors, and intracranial volume.
Alzheimers Dement
December 2024
Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Baden-Wuerttemberg, Germany.
Background: Florzolotau (APN-1607) tau-PET has shown distinct patterns of binding in patients with AD and 4-repeat tauopathies. We aimed to establish disease-specific tau covariance patterns in AD and PSP/CBS and validate them as user-independent quantitative biomarkers for reference-region-free evaluation of tau-PET in an independent clinical cohort.
Method: We analyzed Florzolotau PET data from four different cohorts.
Background: This study set to determine if 123I-ioflupane SPECT striatal binding ratio (SBR) correlated with parkinsonian symptoms measured on Movement Disorder Society - Unified Parkinson's Disease Rating Scale Part III (UPDRS-III) in a dementia with Lewy bodies (DLB) cohort and if SBR measured at baseline could predict progression of parkinsonian symptoms over 2 years.
Methods: This is a retrospective cohort study using the U.S.
Background: Alzheimer's affects women 2:1 compared to men, suggesting sex-specific factors driving risk. Menopause, a female-specific phenomenon, induces a multi-system response across endocrine, metabolic, and immune-inflammatory systems. Despite known effects on these systems, the impact on the brain and AD risk remains incompletely understood, limiting preventative options.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Cleveland Clinic, Cleveland, OH, USA.
Background: This study set to determine if 123I-ioflupane SPECT striatal binding ratio (SBR) correlated with parkinsonian symptoms measured on Movement Disorder Society - Unified Parkinson's Disease Rating Scale Part III (UPDRS-III) in a dementia with Lewy bodies (DLB) cohort and if SBR measured at baseline could predict progression of parkinsonian symptoms over 2 years.
Methods: This is a retrospective cohort study using the U.S.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!